184 related articles for article (PubMed ID: 18813109)
1. PD-L1/PD-1 signal deficiency promotes allogeneic immune responses and accelerates heart allograft rejection.
Wang W; Carper K; Malone F; Latchman Y; Perkins J; Fu Y; Reyes J; Li W
Transplantation; 2008 Sep; 86(6):836-44. PubMed ID: 18813109
[TBL] [Abstract][Full Text] [Related]
2. Peptides derived from alpha-helices of allogeneic class I major histocompatibility complex antigens are potent inducers of CD4+ and CD8+ T cell and B cell responses after cardiac allograft rejection.
Shirwan H; Leamer M; Wang HK; Makowka L; Cramer DV
Transplantation; 1995 Feb; 59(3):401-10. PubMed ID: 7871571
[TBL] [Abstract][Full Text] [Related]
3. Cutting edge: blockade of the CD28/B7 costimulatory pathway inhibits intestinal allograft rejection mediated by CD4+ but not CD8+ T cells.
Newell KA; He G; Guo Z; Kim O; Szot GL; Rulifson I; Zhou P; Hart J; Thistlethwaite JR; Bluestone JA
J Immunol; 1999 Sep; 163(5):2358-62. PubMed ID: 10452966
[TBL] [Abstract][Full Text] [Related]
4. Expression of B7 molecules in recipient, not donor, mice determines the survival of cardiac allografts.
Mandelbrot DA; Furukawa Y; McAdam AJ; Alexander SI; Libby P; Mitchell RN; Sharpe AH
J Immunol; 1999 Oct; 163(7):3753-7. PubMed ID: 10490971
[TBL] [Abstract][Full Text] [Related]
5. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment.
Zheng XX; Markees TG; Hancock WW; Li Y; Greiner DL; Li XC; Mordes JP; Sayegh MH; Rossini AA; Strom TB
J Immunol; 1999 Apr; 162(8):4983-90. PubMed ID: 10202046
[TBL] [Abstract][Full Text] [Related]
6. Loss of myeloid related protein-8/14 exacerbates cardiac allograft rejection.
Shimizu K; Libby P; Rocha VZ; Folco EJ; Shubiki R; Grabie N; Jang S; Lichtman AH; Shimizu A; Hogg N; Simon DI; Mitchell RN; Croce K
Circulation; 2011 Dec; 124(25):2920-32. PubMed ID: 22144572
[TBL] [Abstract][Full Text] [Related]
7. Acute rejection of vascular heart allografts by perforin-deficient mice.
Schulz M; Schuurman HJ; Joergensen J; Steiner C; Meerloo T; Kägi D; Hengartner H; Zinkernagel RM; Schreier MH; Bürki K
Eur J Immunol; 1995 Feb; 25(2):474-80. PubMed ID: 7533086
[TBL] [Abstract][Full Text] [Related]
8. Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival.
Lu L; Li W; Fu F; Chambers FG; Qian S; Fung JJ; Thomson AW
Transplantation; 1997 Dec; 64(12):1808-15. PubMed ID: 9422424
[TBL] [Abstract][Full Text] [Related]
9. The role of donor and recipient B7-1 (CD80) in allograft rejection.
Zheng XX; Sayegh MH; Zheng XG; Li Y; Linsley PS; Peach R; Borriello F; Strom TB; Sharpe AH; Turka LA
J Immunol; 1997 Aug; 159(3):1169-73. PubMed ID: 9233610
[TBL] [Abstract][Full Text] [Related]
10. Induction of donor-specific T cell anergy by portal venous injection of allogeneic cells.
Sugiura K; Kato K; Hashimoto F; Jin T; Amoh Y; Yamamoto Y; Morita H; Okumura K; Ikehara S
Immunobiology; 1997 Nov; 197(5):460-77. PubMed ID: 9413746
[TBL] [Abstract][Full Text] [Related]
11. CD4+ but not CD8+ cells are essential for allorejection.
Krieger NR; Yin DP; Fathman CG
J Exp Med; 1996 Nov; 184(5):2013-8. PubMed ID: 8920888
[TBL] [Abstract][Full Text] [Related]
12. Donor pretreatment with Flt-3 ligand augments antidonor cytotoxic T lymphocyte, natural killer, and lymphokine-activated killer cell activities within liver allografts and alters the pattern of intragraft apoptotic activity.
Qian S; Lu L; Fu F; Li W; Pan F; Steptoe RJ; Chambers FG; Starzl TE; Fung JJ; Thomson AW
Transplantation; 1998 Jun; 65(12):1590-8. PubMed ID: 9665075
[TBL] [Abstract][Full Text] [Related]
13. Trafficking of APC from liver allografts of Flt3L-treated donors: augmentation of potent allostimulatory cells in recipient lymphoid tissue is associated with a switch from tolerance to rejection.
Steptoe RJ; Li W; Fu F; O'Connell PJ; Thomson AW
Transpl Immunol; 1999 Mar; 7(1):51-7. PubMed ID: 10375078
[TBL] [Abstract][Full Text] [Related]
14. LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L.
Lucas CL; Workman CJ; Beyaz S; LoCascio S; Zhao G; Vignali DA; Sykes M
Blood; 2011 May; 117(20):5532-40. PubMed ID: 21422469
[TBL] [Abstract][Full Text] [Related]
15. Creation of chimeric hearts: a tool for testing the "passenger leukocyte" hypothesis.
Eiref SD; Zhang W; Popma SH; Shah LJ; Moore JS; Rosengard BR
Ann Thorac Surg; 1997 Sep; 64(3):628-33. PubMed ID: 9307449
[TBL] [Abstract][Full Text] [Related]
16. On histocompatibility barriers, Th1 to Th2 immune deviation, and the nature of the allograft responses.
Li XC; Zand MS; Li Y; Zheng XX; Strom TB
J Immunol; 1998 Sep; 161(5):2241-7. PubMed ID: 9725217
[TBL] [Abstract][Full Text] [Related]
17. CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway.
Larsen CP; Alexander DZ; Hollenbaugh D; Elwood ET; Ritchie SC; Aruffo A; Hendrix R; Pearson TC
Transplantation; 1996 Jan; 61(1):4-9. PubMed ID: 8560571
[TBL] [Abstract][Full Text] [Related]
18. Contribution of Fas ligand to cardiac allograft rejection.
Seino K; Kayagaki N; Bashuda H; Okumura K; Yagita H
Int Immunol; 1996 Sep; 8(9):1347-54. PubMed ID: 8921411
[TBL] [Abstract][Full Text] [Related]
19. Lymphocyte changes associated with prolongation of cardiac allograft survival in adult mice using anti-CD4 monoclonal antibody.
Pearson TC; Bushell AR; Darby CR; West LJ; Morris PJ; Wood KJ
Clin Exp Immunol; 1993 May; 92(2):211-7. PubMed ID: 8097975
[TBL] [Abstract][Full Text] [Related]
20. CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival.
D'Addio F; Ueno T; Clarkson M; Zhu B; Vergani A; Freeman GJ; Sayegh MH; Ansari MJ; Fiorina P; Habicht A
PLoS One; 2013; 8(4):e60391. PubMed ID: 23593209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
